FR20C1014I2 - Traitement de troubles du cycle sommeil-eveil - Google Patents

Traitement de troubles du cycle sommeil-eveil

Info

Publication number
FR20C1014I2
FR20C1014I2 FR20C1014C FR20C1014C FR20C1014I2 FR 20C1014 I2 FR20C1014 I2 FR 20C1014I2 FR 20C1014 C FR20C1014 C FR 20C1014C FR 20C1014 C FR20C1014 C FR 20C1014C FR 20C1014 I2 FR20C1014 I2 FR 20C1014I2
Authority
FR
France
Prior art keywords
sleep
treatment
wake cycle
cycle disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1014C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of FR20C1014I1 publication Critical patent/FR20C1014I1/fr
Application granted granted Critical
Publication of FR20C1014I2 publication Critical patent/FR20C1014I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR20C1014C 2005-06-08 2020-04-16 Traitement de troubles du cycle sommeil-eveil Active FR20C1014I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
PCT/US2006/022407 WO2006133393A1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders

Publications (2)

Publication Number Publication Date
FR20C1014I1 FR20C1014I1 (enrdf_load_html_response) 2020-06-12
FR20C1014I2 true FR20C1014I2 (fr) 2021-04-23

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1014C Active FR20C1014I2 (fr) 2005-06-08 2020-04-16 Traitement de troubles du cycle sommeil-eveil

Country Status (16)

Country Link
US (8) US8440715B2 (enrdf_load_html_response)
EP (1) EP1890684B1 (enrdf_load_html_response)
JP (1) JP5024635B2 (enrdf_load_html_response)
KR (1) KR101335941B1 (enrdf_load_html_response)
CN (1) CN101217949B (enrdf_load_html_response)
AU (1) AU2006254899B2 (enrdf_load_html_response)
BR (1) BRPI0613697A2 (enrdf_load_html_response)
CA (1) CA2611713C (enrdf_load_html_response)
DK (1) DK1890684T3 (enrdf_load_html_response)
ES (1) ES2435403T3 (enrdf_load_html_response)
FR (1) FR20C1014I2 (enrdf_load_html_response)
NL (1) NL301037I2 (enrdf_load_html_response)
PL (1) PL1890684T3 (enrdf_load_html_response)
RU (1) RU2417077C2 (enrdf_load_html_response)
TW (2) TW201328689A (enrdf_load_html_response)
WO (1) WO2006133393A1 (enrdf_load_html_response)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217949B (zh) 2005-06-08 2012-10-17 爱思开生物制药株式会社 治疗睡眠-清醒病症
US8552060B2 (en) * 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
JP6095366B2 (ja) * 2009-06-22 2017-03-15 エスケー バイオファーマシューティカルズ カンパニー リミテッド 疲労を治療又は予防するための方法
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
WO2011055965A2 (en) * 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
RU2557533C2 (ru) * 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
ES2812586T3 (es) 2013-07-18 2021-03-17 Jazz Pharmaceuticals Ireland Ltd Tratamiento para la obesidad
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016061488A1 (en) * 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥/多動性障害(adhd)の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
CN120574152A (zh) * 2016-09-06 2025-09-02 爱尔兰贾兹制药有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的溶剂化物形式的晶体、其制备方法、组合物及用途
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN110049966A (zh) 2016-10-06 2019-07-23 杰资制药国际三期有限公司 氨基甲酰基苯丙氨醇化合物及其用途
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
US11413264B2 (en) 2017-07-31 2022-08-16 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
WO2024102718A1 (en) * 2022-11-07 2024-05-16 Axsome Therapeutics Compositions and methods for treating insomnia
WO2024118904A1 (en) * 2022-11-30 2024-06-06 Axsome Therapeutics Methods and compositions for improving driving performance
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
ES2170878T3 (es) * 1996-10-10 2002-08-16 Sk Corp Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles.
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
RU2294739C2 (ru) 2001-02-27 2007-03-10 Орто-Макнейл Фармасьютикал, Инк. Производные карбамата для применения для предупреждения или лечения расстройств движений
US6562867B2 (en) 2001-02-27 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
JP2004523554A (ja) 2001-02-27 2004-08-05 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 不安障害の予防もしくは治療における使用のためのカルバメート化合物
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
AU2005302589B2 (en) 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
CN101217949B (zh) * 2005-06-08 2012-10-17 爱思开生物制药株式会社 治疗睡眠-清醒病症
US8552060B2 (en) 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
WO2007018496A1 (en) 2005-07-26 2007-02-15 Janssen Pharmaceutica, N.V. Methods for treating substance-related disorders
EP2079449A2 (en) 2006-10-13 2009-07-22 Janssen Pharmaceutica, N.V. Phenylalkylamino carbamate compositions
JP6095366B2 (ja) 2009-06-22 2017-03-15 エスケー バイオファーマシューティカルズ カンパニー リミテッド 疲労を治療又は予防するための方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
WO2011055965A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy

Also Published As

Publication number Publication date
BRPI0613697A2 (pt) 2011-01-25
US20130137764A1 (en) 2013-05-30
US9604917B2 (en) 2017-03-28
US20140350098A1 (en) 2014-11-27
US20250109099A1 (en) 2025-04-03
WO2006133393A1 (en) 2006-12-14
TWI419681B (zh) 2013-12-21
US12209059B2 (en) 2025-01-28
FR20C1014I1 (enrdf_load_html_response) 2020-06-12
EP1890684A1 (en) 2008-02-27
CN101217949A (zh) 2008-07-09
JP2008545795A (ja) 2008-12-18
CN101217949B (zh) 2012-10-17
PL1890684T3 (pl) 2014-05-30
RU2008100019A (ru) 2009-07-20
TW200716084A (en) 2007-05-01
DK1890684T3 (da) 2013-10-14
EP1890684B1 (en) 2013-08-14
US20090312416A1 (en) 2009-12-17
RU2417077C2 (ru) 2011-04-27
US20240239740A1 (en) 2024-07-18
NL301037I2 (nl) 2020-05-12
NL301037I1 (enrdf_load_html_response) 2020-04-01
JP5024635B2 (ja) 2012-09-12
US20170158622A1 (en) 2017-06-08
CA2611713C (en) 2013-10-01
AU2006254899B2 (en) 2011-11-24
KR20080035565A (ko) 2008-04-23
KR101335941B1 (ko) 2013-12-04
US11753368B2 (en) 2023-09-12
US20210078943A1 (en) 2021-03-18
US8440715B2 (en) 2013-05-14
US20190367448A1 (en) 2019-12-05
ES2435403T3 (es) 2013-12-19
CA2611713A1 (en) 2006-12-14
AU2006254899A1 (en) 2006-12-14
TW201328689A (zh) 2013-07-16
US10351517B2 (en) 2019-07-16
US8877806B2 (en) 2014-11-04

Similar Documents

Publication Publication Date Title
FR20C1014I2 (fr) Traitement de troubles du cycle sommeil-eveil
EP2056673A4 (en) COMBINATION TREATMENT FOR METABOLISM DISEASES
EP1885388A4 (en) TREATMENT AND ASSESSMENT OF INFLAMMATORY DISEASES
EP1968582A4 (en) TREATMENT OF CUTTAN T CELL LYMPHOMA
EP1908486A4 (en) DIALYSIS THERAPY DEVICE
EP1870051A4 (en) MEDICAL THERAPY DEVICE
EP1982660A4 (en) TREATMENT ENDOSCOPE
EP1993528A4 (en) TREATMENT MODULES FOR AUTOIMMUNE DISEASES
EP2046349A4 (en) TREATMENT OF EXCESSIVE NEOVASCULARIZATION
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP2001461A4 (en) COMBINATION TREATMENT FOR METABOLISM DISEASES
EP1755584A4 (en) Treatment of myopia
EP1744751A4 (en) METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
EP1898930A4 (en) Treatment of inflammatory conditions
EP2323641A4 (en) NYASOL AND ANALOGUE THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES
EP1861126A4 (en) TREATMENT OF PROTEIN REMOVAL TROUBLES
FR2912833B1 (fr) Panneau pour le traitement acoustique
EP1962869A4 (en) TREATMENT OF RESPIRATORY DISEASES
EP2176283A4 (en) METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES
EP2303184A4 (en) COMBINATION TREATMENT OF GREEN STAR
EP1943972A4 (en) INSTRUMENT FOR ENDOSCOPIC TREATMENT
EP2032987A4 (en) PHARMACOLOGICAL TREATMENT OF COGNITIVE IMPAIRMENT
FR2901405B1 (fr) Appareils de traitement
EP2247297A4 (en) THERAPEUTIC TREATMENT OF LUNG DISEASES
EP2056858A4 (en) TREATMENT OF LUNG DISEASES